Status of Hemodialysis of Drugs in 2002

Author:

Matzke Gary R.1

Affiliation:

1. Department of Pharmacy and Therapeutics, School of Pharmacy, Division of Renal-Electrolyte Medicine at the School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania,

Abstract

Hemodialysis is a life-sustaining chronic therapy for individuals with end stage renal disease (ESRD). It is also frequently used for days to weeks for patients with acute renal failure who are awaiting the recovery of their kidneys from the acute toxic or traumatic event. Both populations of patients often require complex pharmacotherapeutic regimens, and it is not uncommon for them to be receiving 10 or more concomitant medications. Optimization of care for these patients is dependent on the selection of the most appropriate drug as well as dosage regimen design, which accounts for the influence of hemodialysis therapy on drug disposition. During the last 10 to 15 years there have been several significant changes in the prescribed dose of dialysis and the composition and size of dialyzers available for use. Furthermore, reuse of dialyzers, which was rare in the early 1980s, is now common; it is employed with over 70% of patients with ESRD. The new synthetic dialyzers, which are now used for over 60% of ESRD patients in the United States, are uniformly associated with dramatic improvements in drug removal; dialysis clearance increases of 3 to 10 fold were common for the few drugs evaluated. The influence of these changes in hemodialysis therapy on drug disposition are discussed in a quantitative fashion, and a conceptual framework for drug therapy regimen decision making is presented. For the majority of the drugs reviewed, however, there were no data in the literature regarding dialyzability with currently available dialyzers. The generation of dialyzability data for old and new pharmacotherapeutic agents with state of the art dialysis procedures is clearly needed.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3